Fig. 6
From: Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
VEGFA serum values correlate with tissue expression and radiographic response. a Pre-clinical trial design scheme. b IHC representative images using anti-VEGFA antibody in brain tumor patients (scale bar, 200 μm). Relative VEGFA quantification from tumor sections. Ten fields per section were used to quantify VEGFA-positive counts. Bars represent the relative mean values ± S.D. c Basal VEGFA levels in the plasma and serum obtained from GBM patients prior to bevacizumab treatment (pg/ml). d Correlation between VEGFA values in surgical biopsy and serum (R2 = 0.756, P < 0.05) and plasma (R2 = 0.547, P = 0.153). e VEGFA serum values prior to bevacizumab treatment and follow-up (pg/ml) in responder patients. f–i Axial postcontrast 3D T1-weighted images (f), FLAIR T2-weighted images (g), and DCE (h) perfusion parametric maps of patient 7 prior (upper) and after (bottom) treatment with bevacizumab illustrate tumor response. i A decrease in serum values and on rCBV and Ktrans value. j VEGFA serum values prior to bevacizumab treatment and follow-up (pg/ml) in non-responder patients. k–n Axial postcontrast 3D T1-weighted images (k), FLAIR T2-weighted images (l), and DCE (m) perfusion parametric maps of patient 11 prior (upper) and after (bottom) treatment with bevacizumab demonstrate tumor progression. n An increase in serum values, on rCBV and Ktrans value